CMS And FDA Announce RAPID Coverage Pathway To Speed Patient Access To Medical Devices

CMS and the FDA have started a new process called the RAPID Coverage Pathway. RAPID stands for Regulatory Alignment for Predictable and Immediate Device Coverage.

The idea is to make Medicare coverage faster for some breakthrough medical devices.
A device can get FDA approval, but patients may still have to wait for Medicare coverage. That wait can create problems for patients, doctors, hospitals, and device companies.

With RAPID, CMS and the FDA plan to work together earlier. This should help reduce the gap between FDA approval and Medicare coverage.

What The RAPID Pathway Means

The new pathway applies to certain FDA-designated Class II and Class III breakthrough devices. These are devices that may help patients with serious conditions or medical needs who do not have enough treatment options.

Through RAPID, CMS will work with the FDA and device manufacturers while the device is still being developed. This gives manufacturers a clearer idea of what evidence Medicare may need before deciding coverage.

That matters because FDA approval and Medicare coverage are two different steps. The FDA looks at whether a device is safe and effective. CMS looks at whether Medicare should cover and pay for it.
When both agencies align earlier, companies can plan better studies and avoid delays later.

Why This Change Matters

For Medicare patients, the biggest benefit is faster access.
Some new devices can make a real difference in care, but patients may not benefit quickly if coverage decisions take too long. RAPID is designed to make the coverage process more predictable after FDA authorization.

For manufacturers, it may also reduce confusion. Instead of waiting until the end of the FDA process to understand Medicare expectations, companies can get CMS input earlier.

That can help them collect the right clinical data from the start.

Who Can Use The RAPID Pathway?

The pathway is not for every medical device.

It is meant for certain breakthrough devices that address unmet needs among Medicare beneficiaries. Eligible devices must also be part of an Investigational New Drug study, known as an IDE study.

That study must include Medicare beneficiaries and must track clinical outcomes that both CMS and FDA agree are important.
In simple terms, the device company must show evidence that matters for real Medicare patients, not just for approval paperwork.

How Fast Could Coverage Happen?

Under the RAPID pathway, CMS plans to issue a proposed National Coverage Determination on the same day an eligible device receives FDA market authorization.

After that, there will be a 30-day public comment period.

CMS says this process could allow Medicare coverage and payment as soon as two months after FDA authorization. That is much faster than the usual process, which can take around a year or more in some cases.

What About Other Coverage Pathways?

CMS said it will still keep its other Medicare coverage options available. This includes the normal process for national coverage decisions.

However, CMS will pause new candidates for the Transitional Coverage for Emerging Technologies pathway, also called TCET, while it focuses on RAPID.

The agency says it will use what it learns from these pathways to improve Medicare coverage decisions over time.

What Happens Next?

CMS will publish a proposed notice about the RAPID pathway in the Federal Register. The public will then have 60 days to submit comments.

After reviewing those comments, CMS will publish a final notice. The pathway is expected to begin once that final notice is published.

Bottom Line

The RAPID Coverage Pathway is CMS's and FDA’s attempt to make Medicare coverage faster and clearer for certain breakthrough medical devices.

By working together earlier, both agencies aim to reduce delays, give manufacturers better guidance, and help Medicare patients access new technologies sooner.